This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss and sales beat estimates in the third quarter of 2020.
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View
by Zacks Equity Research
Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance. Stock slides in after-hours trading.
BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.
Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.
Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q3 revenues increase year over year.
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.
Emergent Biosolutions (EBS) Q3 Earnings Top Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up
by Zacks Equity Research
Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales. Recovery in other two segments encouraging.
Zoetis (ZTS) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the third quarter of 2020.
Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) impending third-quarter conference call, investors will keep tabs of its progress with its oral COVID-19 vaccine candidate VXA-CoV2-1.
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
by Zacks Equity Research
Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.
Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y
by Zacks Equity Research
Bayer (BAYRY) misses both earnings and sales estimates in the third quarter of 2020.
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales
by Zacks Equity Research
Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.
Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance
by Zacks Equity Research
Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View
by Zacks Equity Research
Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Emergent Biosolutions (EBS) closed the most recent trading day at $90.77, moving -0.55% from the previous trading session.
Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.